The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients
Open accessAbstract
Nonalcoholic fatty liver disease (NAFLD) is highly prevalent and being overweight is a significant risk factor. The aim was to build an algorithm along with a scoring system for histopathologic classification of liver lesions that covers the entire spectrum of lesions in morbidly obese patients. A cohort of 679 obese patients undergoing liver biopsy at the time of bariatric surgery was studied. An algorithm for segregating lesions into normal liver, NAFLD, or nonalcoholic steatohepatitis (NASH) was built based on semiquantitative evaluation of steatosis, hepatocellular ballooning, and lobular inflammation. For each case, the SAF score was created including the semiquantitative scoring of steatosis (S), activity (A), and fibrosis (F). Based on the algorithm, 230 obese patients (34%) were categorized as NASH, 291 (43%) as NAFLD without NASH, and 158 (23%) as not NAFLD. The activity score (ballooning + lobular inflammation) enabled discriminating NASH because all patients with NASH had A ≥ 2, whereas no patients with A < 2 had NASH. This score was closely correlated with both alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ( P < 0.0001, analysis of variance [ANOVA]). Comparison of transaminase levels between patients with normal liver and pure steatosis did not reveal significant differences, thus lending support to the proposal not to include steatosis in the activity score but to report it separately in the SAF score. In the validation series, the interobserver agreement for the diagnosis of NASH was excellent (κ = 0.80) between liver pathologists. There was no discrepancy between the initial diagnosis and the diagnosis proposed using the algorithm. Conclusion: We propose a simple but robust algorithm for categorizing liver lesions in NAFLD patients. Because liver lesions in obese patients may display a continuous spectrum of histologic lesions, we suggest describing liver lesions using the SAF score.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
An Algorithm for the Grading of Activity in Chronic Hepatitis C
Bedossa, P., & Poynard, T. (1996) · Hepatology · doi:10.1002/hep.510240201 · Cited by 4,088
Self-citationNonalcoholic Steatohepatitis: A Proposal for Grading and Staging The Histological Lesions
Brunt, E. M., Janney, C. G., Di Bisceglie, A. M., Neuschwander-Tetri, B. A., & Bacon, B. R. (1999) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1999.01377.x · Cited by 3,907
Prevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity
Browning, J. D., Szczepaniak, L. S., Dobbins, R., Nuremberg, P., Horton, J. D., Cohen, J. C., Grundy, S. M., & Hobbs, H. H. (2004) · Hepatology · doi:10.1002/hep.20466 · Cited by 3,664
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
Nonalcoholic Fatty Liver Disease
Marchesini, G., Brizi, M., Bianchi, G., Tomassetti, S., Bugianesi, E., Lenzi, M., McCullough, A. J., Natale, S., Forlani, G., & Melchionda, N. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1844 · Cited by 2,581
Triglyceride accumulation protects against fatty acid-induced lipotoxicity
Listenberger, L. L., Han, X., Lewis, S. E., Cases, S., Farese, R. V., Ory, D. S., & Schaffer, J. E. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0630588100 · Cited by 2,075
Dixon, J. B., Bhathal, P. S., & O'Brien, P. E. (2001) · Gastroenterology · doi:10.1053/gast.2001.25540 · Cited by 1,360
Brunt, E. M., Kleiner, D. E., Wilson, L. A., Belt, P., & Neuschwander-Tetri, B. A. (2011) · Hepatology · doi:10.1002/hep.24127 · Cited by 1,251
Research works printed but not linked: 2
- Ratziu, 2012, Touching some firm ground in the epidemiology of NASH., J Hepatol, 56, 2325, 10.1016/j.jhep.2011.08.002 · doi:10.1016/j.jhep.2011.08.002
- Scheuer, 2003, Assessment of liver biopsies in chronic hepatitis: how is it best done?, J Hepatol, 38, 240242, 10.1016/S0168-8278(02)00406-3 · doi:10.1016/s0168-8278(02)00406-3
Cited by
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000520 · Cited by 3,476
“The histological classi fi cation was further expanded on by various scoring systems categorising steatosis, disease activity, and fi brosis [2 − 4].”
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.06.003 · Cited by 3,100
Eddowes, P. J., Sasso, M., Allison, M., Tsochatzis, E., Anstee, Q. M., Sheridan, D., Guha, I. N., Cobbold, J. F., Deeks, J. J., Paradis, V., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.01.042 · Cited by 1,410
Self-citationCellular senescence drives age-dependent hepatic steatosis
Ogrodnik, M., Miwa, S., Tchkonia, T., Tiniakos, D., Wilson, C. L., Lahat, A., Day, C. P., Burt, A., Palmer, A., Anstee, Q. M., et al. (2017) · Nature Communications · doi:10.1038/ncomms15691 · Cited by 1,044
Hagström, H., Nasr, P., Ekstedt, M., Hammar, U., Stål, P., Hultcrantz, R., & Kechagias, S. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.07.027 · Cited by 1,067
Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders
Aron-Wisnewsky, J., Vigliotti, C., Witjes, J., Le, P., Holleboom, A. G., Verheij, J., Nieuwdorp, M., & Clément, K. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0269-9 · Cited by 1,063
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2024) · Annals of Hepatology · doi:10.1016/j.aohep.2023.101133 · Cited by 844
Eslam, M., Sarin, S. K., Wong, V. W.-S., Fan, J.-G., Kawaguchi, T., Ahn, S. H., Zheng, M.-H., Shiha, G., Yilmaz, Y., Gani, R., et al. (2020) · Hepatology International · doi:10.1007/s12072-020-10094-2 · Cited by 833
Nonalcoholic fatty liver disease
Brunt, E. M., Wong, V. W.-S., Nobili, V., Day, C. P., Sookoian, S., Maher, J. J., Bugianesi, E., Sirlin, C. B., Neuschwander-Tetri, B. A., & Rinella, M. E. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.80 · Cited by 818
Bariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients
Lassailly, G., Caiazzo, R., Buob, D., Pigeyre, M., Verkindt, H., Labreuche, J., Raverdy, V., Leteurtre, E., Dharancy, S., Louvet, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.014 · Cited by 762
Non-alcoholic fatty liver disease: An expanded review
Benedict, M., & Zhang, X. (2017) · World Journal of Hepatology · doi:10.4254/wjh.v9.i16.715 · Cited by 751
Cobbina, E., & Akhlaghi, F. (2017) · Drug Metabolism Reviews · doi:10.1080/03602532.2017.1293683 · Cited by 653
NAFLD as a Continuum: From Obesity to Metabolic Syndrome and Diabetes
Godoy-Matos, A. F., Silva Júnior, W. S., & Valerio, C. M. (2020) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-020-00570-y · Cited by 643
Bedossa, P. (2014) · Hepatology · doi:10.1002/hep.27173 · Cited by 625
Self-citationNonalcoholic Fatty Liver Disease: Pathogenesis and Disease Spectrum
Hardy, T., Oakley, F., Anstee, Q. M., & Day, C. P. (2016) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012615-044224 · Cited by 611
Liang, W., Menke, A. L., Driessen, A., Koek, G. H., Lindeman, J. H., Stoop, R., Havekes, L. M., Kleemann, R., & van den Hoek, A. M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0115922 · Cited by 577
Leoni, S., Tovoli, F., Napoli, L., Serio, I., Ferri, S., & Bolondi, L. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i30.3361 · Cited by 539
Wong, V. W., Chan, W., Chitturi, S., Chawla, Y., Dan, Y. Y., Duseja, A., Fan, J., Goh, K., Hamaguchi, M., Hashimoto, E., et al. (2018) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.13857 · Cited by 506
Govaere, O., Cockell, S., Tiniakos, D., Queen, R., Younes, R., Vacca, M., Alexander, L., Ravaioli, F., Palmer, J., Petta, S., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aba4448 · Cited by 479
Self-citationPathophysiology and Mechanisms of Nonalcoholic Fatty Liver Disease
Haas, J. T., Francque, S., & Staels, B. (2016) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021115-105331 · Cited by 394
Histopathology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
Brown, G. T., & Kleiner, D. E. (2016) · Metabolism · doi:10.1016/j.metabol.2015.11.008 · Cited by 363
Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging
Dyson, J. K., Anstee, Q. M., & McPherson, S. (2014) · Frontline Gastroenterology · doi:10.1136/flgastro-2013-100403 · Cited by 357
Challenges and opportunities in NASH drug development
Harrison, S. A., Allen, A. M., Dubourg, J., Noureddin, M., & Alkhouri, N. (2023) · Nature Medicine · doi:10.1038/s41591-023-02242-6 · Cited by 353
Zhao, Z.-H., Xin, F.-Z., Xue, Y., Hu, Z., Han, Y., Ma, F., Zhou, D., Liu, X.-L., Cui, A., Liu, Z., et al. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-019-0304-5 · Cited by 347
Pathological Features of Fatty Liver Disease
Yeh, M. M., & Brunt, E. M. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.07.056 · Cited by 346
Rau, M., Rehman, A., Dittrich, M., Groen, A. K., Hermanns, H. M., Seyfried, F., Beyersdorf, N., Dandekar, T., Rosenstiel, P., & Geier, A. (2018) · United European Gastroenterology Journal · doi:10.1177/2050640618804444 · Cited by 334
Fibrosis and alcohol-related liver disease
Lackner, C., & Tiniakos, D. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.12.003 · Cited by 322
Pathology of non‐alcoholic fatty liver disease
Bedossa, P. (2017) · Liver International · doi:10.1111/liv.13301 · Cited by 322
Self-citationLiu, X., Pan, Q., Cao, H., Xin, F., Zhao, Z., Yang, R., Zeng, J., Zhou, H., & Fan, J. (2020) · Hepatology · doi:10.1002/hep.31050 · Cited by 317
Current treatment of non‐alcoholic fatty liver disease
Paternostro, R., & Trauner, M. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13531 · Cited by 305
Kleiner, D. E., & Makhlouf, H. R. (2016) · Clinics in Liver Disease · doi:10.1016/j.cld.2015.10.011 · Cited by 303
Vali, Y., Lee, J., Boursier, J., Spijker, R., Löffler, J., Verheij, J., Brosnan, M. J., Böcskei, Z., Anstee, Q. M., Bossuyt, P. M., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.036 · Cited by 302
Pharmacotherapy for NASH: Current and emerging
Konerman, M. A., Jones, J. C., & Harrison, S. A. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.10.015 · Cited by 292
Treasure, J., Zipfel, S., Micali, N., Wade, T., Stice, E., Claudino, A., Schmidt, U., Frank, G. K., Bulik, C. M., & Wentz, E. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.74 · Cited by 285
Suppli, M. P., Rigbolt, K. T. G., Veidal, S. S., Heebøll, S., Eriksen, P. L., Demant, M., Bagger, J. I., Nielsen, J. C., Oró, D., Thrane, S. W., et al. (2019) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00358.2018 · Cited by 282
Rom, O., Liu, Y., Liu, Z., Zhao, Y., Wu, J., Ghrayeb, A., Villacorta, L., Fan, Y., Chang, L., Wang, L., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz2841 · Cited by 280
Mouse models of nonalcoholic steatohepatitis in preclinical drug development
Hansen, H. H., Feigh, M., Veidal, S. S., Rigbolt, K. T., Vrang, N., & Fosgerau, K. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.06.007 · Cited by 270
KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease
Kang, S. H., Lee, H. W., Yoo, J.-J., Cho, Y., Kim, S. U., Lee, T. H., Jang, B. K., Kim, S. G., Ahn, S. B., Kim, H., et al. (2021) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2021.0178 · Cited by 267
Non-alcoholic fatty liver disease: A patient guideline
Francque, S. M., Marchesini, G., Kautz, A., Walmsley, M., Dorner, R., Lazarus, J. V., Zelber-Sagi, S., Hallsworth, K., Busetto, L., Frühbeck, G., et al. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2021.100322 · Cited by 264
Vacca, M., Kamzolas, I., Harder, L. M., Oakley, F., Trautwein, C., Hatting, M., Ross, T., Bernardo, B., Oldenburger, A., Hjuler, S. T., et al. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01043-6 · Cited by 262
Self-citationCurrent efforts and trends in the treatment of NASH
Ratziu, V., Goodman, Z., & Sanyal, A. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.041 · Cited by 262
Chiappini, F., Coilly, A., Kadar, H., Gual, P., Tran, A., Desterke, C., Samuel, D., Duclos-Vallée, J.-C., Touboul, D., Bertrand-Michel, J., et al. (2017) · Scientific Reports · doi:10.1038/srep46658 · Cited by 246
Younes, R., Govaere, O., Petta, S., Miele, L., Tiniakos, D., Burt, A., David, E., Vecchio, F. M., Maggioni, M., Cabibi, D., et al. (2022) · Gut · doi:10.1136/gutjnl-2020-322564 · Cited by 205
Younes, R., Caviglia, G. P., Govaere, O., Rosso, C., Armandi, A., Sanavia, T., Pennisi, G., Liguori, A., Francione, P., Gallego-Durán, R., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.05.008 · Cited by 196
Hammoutene, A., Biquard, L., Lasselin, J., Kheloufi, M., Tanguy, M., Vion, A.-C., Mérian, J., Colnot, N., Loyer, X., Tedgui, A., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.10.028 · Cited by 188
Self-citationNonalcoholic steatohepatitis: a search for factual animal models
Sanches, S. C. L., Ramalho, L. N. Z., Augusto, M. J., da Silva, D. M., & Ramalho, F. S. (2015) · BioMed Research International · doi:10.1155/2015/574832 · Cited by 174
Mosca, A., Nobili, V., De Vito, R., Crudele, A., Scorletti, E., Villani, A., Alisi, A., & Byrne, C. D. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.12.025 · Cited by 161
Haas, J. T., Vonghia, L., Mogilenko, D. A., Verrijken, A., Molendi-Coste, O., Fleury, S., Deprince, A., Nikitin, A., Woitrain, E., Ducrocq-Geoffroy, L., et al. (2019) · Nature Metabolism · doi:10.1038/s42255-019-0076-1 · Cited by 155
Heebøll, S., Kreuzfeldt, M., Hamilton-Dutoit, S., Kjær Poulsen, M., Stødkilde-Jørgensen, H., Møller, H. J., Jessen, N., Thorsen, K., Kristina Hellberg, Y., Bønløkke Pedersen, S., et al. (2016) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365521.2015.1107620 · Cited by 154
Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease
Boyle, M., Tiniakos, D., Schattenberg, J. M., Ratziu, V., Bugianessi, E., Petta, S., Oliveira, C. P., Govaere, O., Younes, R., McPherson, S., et al. (2019) · JHEP Reports · doi:10.1016/j.jhepr.2019.06.004 · Cited by 140
Somm, E., Montandon, S. A., Loizides-Mangold, U., Gaïa, N., Lazarevic, V., De Vito, C., Perroud, E., Bochaton-Piallat, M.-L., Dibner, C., Schrenzel, J., et al. (2021) · Translational Research · doi:10.1016/j.trsl.2020.07.008 · Cited by 118
Adori, C., Daraio, T., Kuiper, R., Barde, S., Horvathova, L., Yoshitake, T., Ihnatko, R., Valladolid-Acebes, I., Vercruysse, P., Wellendorf, A. M., et al. (2021) · Science Advances · doi:10.1126/sciadv.abg5733 · Cited by 105
Circulating phospholipid profiling identifies portal contribution to NASH signature in obesity
Anjani, K., Lhomme, M., Sokolovska, N., Poitou, C., Aron-Wisnewsky, J., Bouillot, J.-L., Lesnik, P., Bedossa, P., Kontush, A., Clement, K., et al. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2014.11.002 · Cited by 106
Self-citationGastaldelli, A., Sabatini, S., Carli, F., Gaggini, M., Bril, F., Belfort‐DeAguiar, R., Positano, V., Barb, D., Kadiyala, S., Harrison, S., et al. (2021) · Liver International · doi:10.1111/liv.15005 · Cited by 101
Tiwari-Heckler, S., Gan-Schreier, H., Stremmel, W., Chamulitrat, W., & Pathil, A. (2018) · Nutrients · doi:10.3390/nu10050649 · Cited by 96
Chang, D., Truong, E., Mena, E. A., Pacheco, F., Wong, M., Guindi, M., Todo, T. T., Noureddin, N., Ayoub, W., Yang, J. D., et al. (2023) · Hepatology · doi:10.1002/hep.32655 · Cited by 92
Kendall, T. J., Jimenez-Ramos, M., Turner, F., Ramachandran, P., Minnier, J., McColgan, M. D., Alam, M., Ellis, H., Dunbar, D. R., Kohnen, G., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02602-2 · Cited by 92
Nachit, M., De Rudder, M., Thissen, J., Schakman, O., Bouzin, C., Horsmans, Y., Vande Velde, G., & Leclercq, I. A. (2021) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12646 · Cited by 82
Lan, T., Hu, Y., Hu, F., Li, H., Chen, Y., Zhang, J., Yu, Y., Jiang, S., Weng, Q., Tian, S., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.09.040 · Cited by 75
Pafili, K., Kahl, S., Mastrototaro, L., Strassburger, K., Pesta, D., Herder, C., Pützer, J., Dewidar, B., Hendlinger, M., Granata, C., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.08.010 · Cited by 67
Bone morphogenetic protein 8B promotes the progression of non-alcoholic steatohepatitis
Vacca, M., Leslie, J., Virtue, S., Lam, B. Y. H., Govaere, O., Tiniakos, D., Snow, S., Davies, S., Petkevicius, K., Tong, Z., et al. (2020) · Nature Metabolism · doi:10.1038/s42255-020-0214-9 · Cited by 60
Gancheva, S., Kahl, S., Pesta, D., Mastrototaro, L., Dewidar, B., Strassburger, K., Sabah, E., Esposito, I., Weiß, J., Sarabhai, T., et al. (2022) · Diabetes Care · doi:10.2337/dc21-1758 · Cited by 60
Rosso, C., Caviglia, G. P., Birolo, G., Armandi, A., Pennisi, G., Pelusi, S., Younes, R., Liguori, A., Perez-Diaz-del-Campo, N., Nicolosi, A., et al. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.04.024 · Cited by 59
Azzu, V., Vacca, M., Kamzolas, I., Hall, Z., Leslie, J., Carobbio, S., Virtue, S., Davies, S. E., Lukasik, A., Dale, M., et al. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101210 · Cited by 52
Fred, R. G., Steen Pedersen, J., Thompson, J. J., Lee, J., Timshel, P. N., Stender, S., Opseth Rygg, M., Gluud, L. L., Bjerregaard Kristiansen, V., Bendtsen, F., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-16754-7 · Cited by 44
Authors, & Collaborators: (2022) · Zeitschrift für Gastroenterologie · doi:10.1055/a-1880-2388 · Cited by 30
Russo, M. F., Lembo, E., Mari, A., Angelini, G., Verrastro, O., Nanni, G., Pompili, M., Raffaelli, M., Vecchio, F. M., Bornstein, S. R., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa892 · Cited by 28
Verhaegh, P., Wisse, E., de Munck, T., Greve, J. W., Verheij, J., Riedl, R., Duimel, H., Masclee, A., Jonkers, D., & Koek, G. (2021) · Pathology · doi:10.1016/j.pathol.2020.07.018 · Cited by 22
Chen, L., Huang, Y., Zhang, N., Qu, J., Fang, Y., Fu, J., Yuan, Y., Zhang, Q., Li, H., Wen, Z., et al. (2024) · MedComm · doi:10.1002/mco2.654 · Cited by 15
Metadata
- Authors
- Bedossa, P., Poitou, C., Veyrie, N., Bouillot, J.-L., Basdevant, A., Paradis, V., Tordjman, J., & Clement, K.
- Venue
- Hepatology
- Published
- 2012-11
- Volume
- 56
- Issue
- 5
- Pages
- 1751-1759
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2060205727
- Cited by
- 903
- References
- 28
- FWCI
- 15.73
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 1034 d)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.